Hepatocellular carcinoma (HCC) is one of the most common solid malignancies worldwide.
A large proportion of patients with HCC are diagnosed at advanced stages and are only …

Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Abstract Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …

Oncolytic viruses (OVs) provide novel and promising therapeutic options for patients with
cancers resistant to traditional therapies. Natural or genetically modified OVs are …

Immune checkpoint blockade (ICB) therapy shows excellent efficacy against malignancies;
however, insufficient tumor immunogenicity and the immunosuppressive tumor …

Oncolytic viruses (OVs) represent a new class of multi-modal immunotherapies for cancer,
with OV-elicited antitumor immunity being key to their overall therapeutic efficacy. Currently …

Despite the superior tumor lytic efficacy of oncolytic viruses (OVs), their systemic delivery still
faces the challenges of limited circulating periods, poor tumor tropism, and spontaneous …

Oncolytic adenovirus (Ad) infection promotes intracellular autophagy in tumors. This could
kill cancer cells and contribute to Ads-mediated anticancer immunity. However, the low …

The efficacy of oncolytic adenoviruses (OAs) for cancer therapy has been limited by
insufficient delivery to tumors after systemic injection and the propensity of OAs to induce the …

Photoimmunotherapy is an emerging treatment modality that uses photothermal,
photodynamic and photochemical processes to fight against cancer by eliciting a robust host …